Skip to content

GM3 and insulin sensitivity.

GM3 and insulin sensitivity.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON21599
Enrollment
20
Registered
2008-11-18
Start date
2008-12-10
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, obesity, insulin resistance,

Interventions

None: This is a comparitive study
10 obese men mached for gender and age with 10 lean men.

Sponsors

Academic Medical Center (AMC), Department of Endocrinology and Metabolism
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria for all participants 1. Written informed consent 2. Caucasian 3. Able to keep a normal day and night rhythm during the study period (i.e. no shift work) 4. Stable weight for at least 3 months 5. Age 20-55 years Inclusion criteria for healthy volunteers: 1. 20 ¡Ü BMI ¡Ü 25 kg/m2 2. Fasting glucose level of 30 kg/m2 2. Fasting glucose level of 2.7

Exclusion criteria

Exclusion criteria: Exclusion criteria for all participants: 1. Participation in an investigational drug trial within 90 days prior to our study 2. history of or current abuse of drugs or alcohol (>14 U/week) 3. Smoking 4. Vigorous physical activity 5. Family history of DM II 6. Familial dyslipidemia 7. Any medical condition except hypertension and dyslipidemia in the obese group 8. Use of any medication except for anti-hypertensives, excluding ACE-inhibitors/AII-antagonists.

Design outcomes

Primary

MeasureTime frame
- Peripheral glucose uptake (Rd) - Ganglisosides concentration in muscle and adipose tissue

Secondary

MeasureTime frame
- Plasma concentration of glucoregulatory hormones - Energy expenditure - Carbohydrate oxidation and fat oxidation - VO2 max - Muscle fiber type

Contacts

Public ContactM. Brands

Academic Medical Center (AMC) F5-162 Endocrinology and Metabolism

m.brands@amc.uva.nl+31 (0)20 5662663

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)